ACINO INTERNATIONAL - Comprehensive Analysis Report

Summary

ACINO INTERNATIONAL AG is a Swiss pharmaceutical company with a history spanning nearly two centuries, evolving from a chemicals enterprise to a specialized pharmaceutical and biotechnology firm. Headquartered in Zurich and founded in 1836 as "Schweizerhall," Acino's core mission is to develop, manufacture, and internationally market innovative and proven pharmaceuticals leveraging novel drug delivery forms. The company is committed to providing high-quality, affordable healthcare solutions, with a particular focus on high-growth emerging markets. Acino plays a significant role in its industry, distinguished by its leadership in oral solid dose (OSD) product manufacturing and its efforts to enhance access to essential medicines across diverse global geographies.

1. Strategic Focus & Objectives

Core Objectives

Acino's primary objectives revolve around delivering high-quality pharmaceuticals to patients in emerging markets across Africa, Latin America, the Middle East, Türkiye, Ukraine, and other Eurasian countries. The company aims to expand its geographic footprint and strengthen its innovation portfolio through strategic partnerships and targeted acquisitions. Digital transformation initiatives, such as the digital lab project, are integral to its operational strategy, focused on modernizing quality control and testing processes.

Specialization Areas

Acino specializes in advanced drug delivery technologies, predominantly focusing on oral solid dose (OSD) products. Expertise includes dispersible and complex modified release formulations, such as Multi-Unit Pellet System (MUPS) and minitablets. The company also has capabilities in transdermal systems and extended-release parenterals. Its unique value proposition lies in its ability to offer both originator brands and branded generics, addressing diverse patient needs with high-quality, accessible medicines.

Target Markets

Acino primarily targets high-growth emerging markets. These include key regions across the Middle East, Africa, Ukraine, Eurasian countries, and Latin America. The company's market positioning strategy emphasizes addressing underserviced regions to improve patient access to medicines, leveraging its advanced drug delivery capabilities for localized solutions.

2. Financial Overview

Funding History

Acino became part of Arcera in 2022, a global life sciences platform established by ADQ, a prominent Abu Dhabi-based investment and holding company. ADQ acquired Acino, and subsequently, in 2024, consolidated its life sciences assets under the Arcera umbrella. For the full year 2023, Acino reported group sales exceeding $653 million, with approximately 88% of these sales generated in its target high-growth markets. Arcera has set an ambitious goal to double its revenue over the next five years through a strategy combining acquisitions and global partnerships.

3. Product Pipeline

Key Products/Services

Acino's product portfolio is comprehensive, encompassing Prescription (Rx) medicines, Over-the-Counter (OTC) medicines, food supplements, and cosmetics, offering both originator brands and branded generics. Its primary therapeutic areas include:
Cardiovascular & Metabolism
Gastroenterology
Infectious diseases
Neurosciences
Pain & Rheumatology

Specifically, through its acquisition of M8 Pharmaceuticals in Latin America, Acino is commercializing innovative medicines such as:
QELBREE® (viloxazine extended-release capsules): For ADHD, currently undergoing Phase 4 clinical trials, including studies in combination with psychostimulants for children and adolescents, and a planned trial for preschool-age children with ADHD.
VORAXAZE® (Glucarpidase)
ZEMIGLO®
ZEMINET®
HYRUAN ONE®

4. Technology & Innovation

Technology Stack

Acino is a leader in advanced drug delivery technologies, with a strong focus on oral solid dosage forms. Its core platforms and proprietary developments include:
Modified Release Oral Forms: Designing pharmaceuticals for controlled drug release over extended periods.
Oral Dispersible Forms: Enabling easier administration, particularly for patients with swallowing difficulties.
Transdermal Systems: Patented technology for transdermal therapeutic systems, including applicators for implants and reservoir systems with closed membranes.
Extended-Release Parenterals: Advanced formulations for injectable medications with prolonged effects.
The company is also implementing a "digital lab" initiative, a significant digital transformation project aimed at modernizing quality control and testing by streamlining workflows and eliminating non-value-adding tests.

5. Leadership & Management

Executive Team

Acino's leadership team comprises seasoned professionals with deep expertise in the pharmaceutical sector:
Isabel Afonso: Chief Executive Officer of Arcera (Acino's parent company). Appointed in 2023, she previously held positions as International Head of In-Market Brands & Business Innovation at Novartis and Chief Commercial Officer at Performance Health.
Andrew Bird: Interim CEO of Acino (as of June 2023). He previously served as General Manager and Head of Region, Middle East, Turkey and Africa.
Mansoor Meenai: Head of Middle East, Türkiye, and Africa at Arcera (as of 2025). He was formerly Interim Head of Middle East, Türkiye, and Africa at Acino and Finance Director META Region.
Andrés García Baquero: Head of LATAM at Acino and M8, part of Arcera. His prior experience includes Vice-President Sales LATAM at P&G Health.
Samir El Nasharty: Chief Operations Officer at Acino, leading a global team of over 1,000 Tech Ops professionals.
John Norman: Head of Africa at Arcera (as of 2025). He was Head of Africa at Acino from 2018 to 2025.
Eugene Zaika: Head of Ukraine and Eurasian countries at Arcera (as of 2025). He served as Head of Ukraine and Eurasian countries at Acino from 2015 to 2025.
Max Sorokin: Chief Financial Officer at Acino International AG.

Recent Leadership Changes

There have been several key leadership transitions within Acino and its parent organization, Arcera:
Sunil Bhilotra was appointed Managing Director and interim Chief Executive Officer of Acino in October 2022, succeeding Steffen Saltofte.
Andrew Bird subsequently took over as interim CEO of Acino in June 2023.
Mansoor Meenai transitioned from Interim Head of Region, Middle East, Türkiye, and Africa at Acino to Head of Middle East, Türkiye, and Africa at Arcera in 2025.
Isabel Afonso became the Chief Executive Officer of Arcera in 2023, following her role as International Head of In-Market Brands & Business Innovation at Novartis.
John Norman and Eugene Zaika also transitioned to their respective Head of Region roles at Arcera in 2025.

6. Talent and Growth Indicators

Hiring Trends and Workforce

Acino concluded 2023 with 2,848 employees, with current figures indicating a workforce exceeding 3,000 individuals globally. The company is actively expanding its global team and planning to integrate additional sites and staff as part of its growth strategy. Acino's commitment to its workforce is evident in its consistent recognition for employee practices:
Top Employer Certification: Acino South Africa has been certified as a "Top Employer" by the Top Employers Institute for five consecutive years, including in January 2026.
Best Place to Work: Acino Iraq received "Best Place to Work" recognition in November 2025.
B-BBEE Status: Acino achieved Level 1 B-BBEE status in South Africa for the sixth consecutive year in May 2025, demonstrating its commitment to Broad-Based Black Economic Empowerment.
The company is dedicated to fostering a positive work environment, offering comprehensive learning and development programs, and cultivating a diverse and multicultural team. Employee well-being is a priority, with provisions for mental health services and flexible working policies. These indicators highlight a robust and growing organization focused on attracting, developing, and retaining talent.

7. Social Media Presence and Engagement

Digital Footprint

Acino maintains an active and engaged presence across various social media platforms to connect with stakeholders and foster community. The company encourages respectful interaction, including likes, shares, @mentions, comments, and direct messages. Acino publishes specific community guidelines emphasizing cordiality, accuracy of information, and the prohibition of inappropriate content or medical advice.
LinkedIn: [https://www.linkedin.com/company/acino](https://www.linkedin.com/company/acino)
Facebook: [https://www.facebook.com/acino.swiss/](https://www.facebook.com/acino.swiss/)
X (formerly Twitter): [https://twitter.com/acino_pharma](https://twitter.com/acino_pharma)
YouTube: [https://www.youtube.com/@acinopharma](https://www.youtube.com/@acinopharma)
Instagram: [https://www.instagram.com/acino.swiss/](https://www.instagram.com/acino.swiss/)

8. Recognition and Awards

Industry Recognition

Acino has garnered several notable recognitions and awards that underscore its commitment to operational excellence and employee welfare:
Top Employer Certification: Acino South Africa was certified as a Top Employer for the fifth consecutive year in January 2026 by the Top Employers Institute.
Best Place to Work: Acino Iraq was recognized as a "Best Place to Work" in November 2025.
B-BBEE Status: The company achieved Level 1 B-BBEE (Broad-Based Black Economic Empowerment) status in South Africa for the sixth consecutive year in May 2025.

9. Competitive Analysis

Major Competitors

Acino navigates a highly competitive global pharmaceutical landscape, particularly within emerging markets and specialized drug delivery systems. Its competitive set includes:
Specialized Pharmaceutical and CDMO/CROs: GxMed, Midas Pharma, Veriton Pharma, Ardena (pharmaceutical contract development and manufacturing organization), Simbec-Orion (contract research organization), Grand River Aseptic Manufacturing (parenteral contract development and manufacturing organization), and Uquifa (active pharmaceutical ingredient manufacturer). These direct competitors often focus on similar niche areas or provide specific services within the pharmaceutical value chain.
Large Multinational Pharmaceutical Companies: Broader competitors in the global market include industry giants such as Roche, Teva Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Sanofi, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, AstraZeneca, Mylan, Novartis, Sandoz, and Eli Lilly and Company. While many of these operate on a larger scale, they still compete with Acino in specific therapeutic areas or geographic markets.

10. Market Analysis

Market Overview

Acino's primary market focus on high-growth emerging markets in the Middle East, Africa, Ukraine, Eurasian countries, and Latin America represents a total addressable market with significant growth potential. These regions are characterized by increasing demand for affordable, high-quality pharmaceuticals, driven by growing populations and expanding middle classes.
Key market trends influencing Acino's strategy include:
Rise of Personalized Medicine: A growing industry trend towards tailored treatments, which Acino aims to address.
Digital Transformation: Continued investment in digital tools and initiatives, seen in Acino's digital lab project, is crucial for efficiency and innovation.
Strategic Partnerships: These are vital for geographic expansion and enhancing innovation capabilities.
Pharmaceutical Contract Manufacturing: The market for oral solid dosages is dynamic and a key sector where Acino maintains a significant presence.
Market challenges often include regulatory complexities, diverse healthcare infrastructures, and the need for robust supply chain resilience in these regions. Acino's strategy explicitly targets addressing underserviced regions to improve patient access to essential medicines, turning these challenges into opportunities for growth and social impact.

11. Strategic Partnerships

Acino actively pursues strategic collaborations and acquisitions to enhance its market position, expand its geographic reach, and strengthen its capabilities.
Key strategic moves and partnerships include:
Acquisition of M8 Pharmaceuticals (2023): Significantly expanded Acino’s presence and capabilities in Latin America, providing access to major markets like Mexico and Brazil.
Integration of Pharmax Pharmaceuticals (2023): This integration into Acino’s Middle East operations added a GCC and EU GMP-certified manufacturing site in Dubai.
Acquired by ADQ (2022): Acino became a core component of Arcera, a global life sciences platform established by ADQ.
Exclusive Licensing and Supply Agreements